INDAPTUS THERAPEUTICS INC (INDP) Fundamental Analysis & Valuation
NASDAQ:INDP • US45339J2042
Current stock price
1.57 USD
-0.03 (-1.88%)
At close:
1.55 USD
-0.02 (-1.27%)
Pre-Market:
This INDP fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.
1. INDP Profitability Analysis
1.1 Basic Checks
- In the past year INDP has reported negative net income.
- INDP had a negative operating cash flow in the past year.
- INDP had negative earnings in each of the past 5 years.
- INDP had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
- Looking at the Return On Assets, with a value of -223.94%, INDP is doing worse than 90.52% of the companies in the same industry.
- Looking at the Return On Equity, with a value of -661.53%, INDP is doing worse than 79.69% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -223.94% | ||
| ROE | -661.53% | ||
| ROIC | N/A |
ROA(3y)-177.33%
ROA(5y)-120.4%
ROE(3y)-390.01%
ROE(5y)-249.93%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
- The Profit Margin and Operating Margin and Gross Margin are not available for INDP so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. INDP Health Analysis
2.1 Basic Checks
- The number of shares outstanding for INDP has been increased compared to 1 year ago.
- INDP has more shares outstanding than it did 5 years ago.
- INDP has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
2.2 Solvency
- INDP has an Altman-Z score of -18.50. This is a bad value and indicates that INDP is not financially healthy and even has some risk of bankruptcy.
- Looking at the Altman-Z score, with a value of -18.50, INDP is doing worse than 82.40% of the companies in the same industry.
- INDP has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -18.5 |
ROIC/WACCN/A
WACCN/A
2.3 Liquidity
- INDP has a Current Ratio of 1.51. This is a normal value and indicates that INDP is financially healthy and should not expect problems in meeting its short term obligations.
- With a Current ratio value of 1.51, INDP is not doing good in the industry: 82.20% of the companies in the same industry are doing better.
- INDP has a Quick Ratio of 1.51. This is a normal value and indicates that INDP is financially healthy and should not expect problems in meeting its short term obligations.
- INDP has a Quick ratio of 1.51. This is amonst the worse of the industry: INDP underperforms 80.46% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.51 | ||
| Quick Ratio | 1.51 |
3. INDP Growth Analysis
3.1 Past
- INDP shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 43.69%, which is quite impressive.
EPS 1Y (TTM)43.69%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%57.61%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
3.2 Future
- Based on estimates for the next years, INDP will show a quite strong growth in Earnings Per Share. The EPS will grow by 17.67% on average per year.
- No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y74.32%
EPS Next 2Y34.95%
EPS Next 3Y26.83%
EPS Next 5Y17.67%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
- No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
4. INDP Valuation Analysis
4.1 Price/Earnings Ratio
- INDP reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
- Also next year INDP is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
- INDP's earnings are expected to grow with 26.83% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y34.95%
EPS Next 3Y26.83%
5. INDP Dividend Analysis
5.1 Amount
- INDP does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
INDP Fundamentals: All Metrics, Ratios and Statistics
1.57
-0.03 (-1.88%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)03-17 2026-03-17/amc
Earnings (Next)05-12 2026-05-12
Inst Owners3.94%
Inst Owner Change0%
Ins Owners27.45%
Ins Owner Change0.03%
Market Cap3.52M
Revenue(TTM)N/A
Net Income(TTM)-20.85M
Analysts82.86
Price Target10.2 (549.68%)
Short Float %0.63%
Short Ratio0.19
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)14.26%
Min EPS beat(2)-1.41%
Max EPS beat(2)29.94%
EPS beat(4)2
Avg EPS beat(4)-10.55%
Min EPS beat(4)-74.29%
Max EPS beat(4)29.94%
EPS beat(8)6
Avg EPS beat(8)5.45%
EPS beat(12)10
Avg EPS beat(12)10.17%
EPS beat(16)14
Avg EPS beat(16)13.69%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | N/A | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 1.12 | ||
| P/tB | 1.12 | ||
| EV/EBITDA | N/A |
EPS(TTM)-25.54
EYN/A
EPS(NY)-6.56
Fwd EYN/A
FCF(TTM)-6.62
FCFYN/A
OCF(TTM)-6.62
OCFYN/A
SpS0
BVpS1.41
TBVpS1.41
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -223.94% | ||
| ROE | -661.53% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM | N/A |
ROA(3y)-177.33%
ROA(5y)-120.4%
ROE(3y)-390.01%
ROE(5y)-249.93%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | N/A | ||
| Cap/Sales | N/A | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 1.51 | ||
| Quick Ratio | 1.51 | ||
| Altman-Z | -18.5 |
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)43.69%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%57.61%
EPS Next Y74.32%
EPS Next 2Y34.95%
EPS Next 3Y26.83%
EPS Next 5Y17.67%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-29.08%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-20.29%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-20.29%
OCF growth 3YN/A
OCF growth 5YN/A
INDAPTUS THERAPEUTICS INC / INDP Fundamental Analysis FAQ
Can you provide the ChartMill fundamental rating for INDAPTUS THERAPEUTICS INC?
ChartMill assigns a fundamental rating of 2 / 10 to INDP.
What is the valuation status for INDP stock?
ChartMill assigns a valuation rating of 1 / 10 to INDAPTUS THERAPEUTICS INC (INDP). This can be considered as Overvalued.
What is the profitability of INDP stock?
INDAPTUS THERAPEUTICS INC (INDP) has a profitability rating of 0 / 10.
Can you provide the expected EPS growth for INDP stock?
The Earnings per Share (EPS) of INDAPTUS THERAPEUTICS INC (INDP) is expected to grow by 74.32% in the next year.